Stauft Charles B, Selvaraj Prabhuanand, Lien Christopher Z, Starost Matthew F, Wang Tony T
Division of Viral Products, Center for Biologics Evaluations and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Division of Veterinary Resources, Diagnostic and Research Services Branch, National Institutes of Health, Bethesda, Maryland, USA.
J Med Virol. 2022 Jun;94(6):2833-2836. doi: 10.1002/jmv.27641. Epub 2022 Feb 28.
COVID-19 vaccines provide high levels of protection against severe disease and hospitalization due to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. Vaccination may be less effective in preventing shedding of infectious viruses from otherwise immune patients. In this study, we describe breakthrough infections and shedding of infectious viruses in convalescent hamsters without significant replication in the lower respiratory tract following reinfection by Alpha and Delta variants despite high levels of circulating antibodies in sera. Using convalescent hamsters with long-term immunity (up to 1 year) following infection by ancestral SARS-CoV-2, we can model aspects of recurring COVID-19 in the context of preexisting immunity.
新冠病毒疫苗对严重急性呼吸综合征相关冠状病毒2(SARS-CoV-2)感染所致的重症疾病和住院提供高水平保护。接种疫苗在预防已产生免疫的患者排出传染性病毒方面可能效果较差。在本研究中,我们描述了恢复期仓鼠的突破性感染和传染性病毒排出情况,尽管血清中循环抗体水平很高,但在被阿尔法和德尔塔变异株再次感染后,下呼吸道中病毒并无显著复制。利用感染原始SARS-CoV-2后具有长期免疫力(长达1年)的恢复期仓鼠,我们可以在已有免疫力的背景下模拟复发性新冠肺炎的一些情况。